Pipeline-In-A-Pill: Still A Winning Strategy?

“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.

Pills
• Source: Shutterstock

Life cycle management (LCM) is an expression that conjures up thoughts of price increases, “evergreening” and patent litigation – all of which carry negative connotations. But LCM is a fundamental part of every successful drug, with many separate strategies underpinning the growth profiles and longevity of the industry’s top-selling drugs.

Pipeline-in-a-pill is one such strategy, clearly evident with the 10 indications of Humira (adalimumab), or 100-plus pages that constitute Keytruda’s...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo